Key Financial Figures
Q2 FY27 Performance:
- Revenue from operations: ₹206 crore (vs. ₹200 crore in Q2 FY26), growth of 3.2% YoY
- EBITDA: ₹45 crore (vs. ₹73 crore in Q2 FY26), decline of 37.5% YoY
- EBITDA margin: 22% (vs. 36.5% in Q2 FY26)
- PAT: ₹29 crore (vs. ₹50 crore in Q2 FY26)
- PAT margin: 14.2%
H1 FY27 Performance:
- Revenue from operations: ₹396 crore (vs. ₹345 crore in H1 FY26), growth of 14.8% YoY
- EBITDA: ₹93 crore (vs. ₹124 crore in H1 FY26), degrowth of 25.3% YoY
- EBITDA margin: 23.4%
- PAT: ₹53 crore (vs. ₹85 crore in H1 FY26)
- PAT margin: 13.5%
Capital Expenditure:
- Q2 FY27 capex: ₹18.8 crore
- H1 FY27 capex: ₹35.4 crore
- Capex primarily driven by Ambernath facility, maintenance capex, Ribo block, and formulation plant requirements
Operational Highlights
Geographic Revenue Mix (Q2 FY27):
- Exports contributed 80% of total revenue
- Europe: 43% of exports
- Asia: 36% of exports
- LATAM: 12% of exports (down from 21% in previous periods)
Backward Integration:
- Fully backward integrated products now account for approximately 74% of total revenue
New Product Launches:
- Launched 2 new anesthetic liquid inhalation products from Ambernath facility during Q2 FY27
- Products are in early stages of commercialization with contribution expected to increase progressively
- 2 ADHD products in pipeline
- Contrast media product expected to launch in next quarter
- Whey protein samples approved by customers; commercial POs expected
Ambernath Facility Status:
- Currently in ramp-up phase with higher operating expenses impacting margins
- EU audit scheduled for November 2026 (next week after call)
- Facility designed to generate ₹450-500 crore revenue at full capacity
- Expected to reach breakeven at ₹160-200 crore revenue, likely in 1-1.5 years after approvals
- Currently generating minimal revenue due to regulatory approval delays
Management Guidance Revision
Revenue Guidance:
- Maintains ₹1,000 crore revenue target for FY27
- Expects 20%+ growth trajectory to continue in future years
EBITDA Margin Guidance:
- Revises FY27 EBITDA margin guidance downward to 23-25% (from previous 32-35%)
- Expects margin profile to improve progressively in FY28 as Ambernath commercial sales scale up, product mix improves, and raw material costs normalize
Factors Impacting Margins
Management attributed the margin decline to three main factors contributing approximately 6% each to the 12-13% margin reduction:
1. Ambernath Facility Expenses: ₹60 crore full-year expense impact with minimal revenue contribution
2. LATAM Regulatory Changes: Recent classification of high-margin controlled substances in Colombia, Peru, Uruguay requiring import authorizations
3. Raw Material and Solvent Prices: Continued high prices due to geopolitical tensions and war
Growth Drivers
Management identified three main growth drivers:
1. Existing baseline business continuing to grow across regulated markets
2. New product launches showing good traction in semi-regulated and domestic markets
3. CMO/CDMO opportunities, including a large anesthetic contract close to signing
Other Business Updates
Management Appointment:
- Mr. Mangesh Vaze joined as Chief Operating Officer with over 30 years of API manufacturing experience
Legal Matter:
- Employee bail granted in unspecified case; company has provided full financial support to family
- Matter moving to Supreme Court for quashing, with positive verdict expected by December 15, 2026
Borrowings:
- No utilization of working capital limits except for letters of credit and bank guarantees
Q&A Key Takeaways
- LATAM regulatory impact is timing-related, not demand destruction, with import permits expected in 4-5 months
- Raw material price increases being passed to customers with 2-3 quarter lag
- Large CMO contract initial years will be API-focused, not dependent on Ambernath approvals
- Statins intermediate scale-up progressing well with competitive positioning against China
- ADHD products have API market potential of $100-150 million